SLC25A1 and metabolic dysfunction-associated steatohepatitis: Similar to our findings in CRC, a previous study in inflammatory steatohepatitis (NASH) also showed that suppression of SLC25A1 with CTPI-2 (a specific inhibitor of SLC25A1) reverted steatosis, glucose intolerance, and inflammation in the liver tissue [13].